Pre-made Moxetumomab benchmark antibody ( Fv Fusion, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Moxetumomab biosimilar, Fv Fusion, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Moxetumomab pasudotox-tdfk injection is used to treat hairy cell leukemia that has worsened or cannot be completely removed in patients who have had at least two previous treatments that did not work well.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-358-1mg	1mg	Inquiry
GMP-Bios-ab-358-10mg	10mg	Inquiry
GMP-Bios-ab-358-100mg	100mg	Inquiry
GMP-Bios-ab-358-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Moxetumomab biosimilar, Fv Fusion, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
INN Name	Moxetumomab
Target	CD22
Format	Fv Fusion
Derivation
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	National Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA)
Conditions Approved	Hairy cell leukaemia
Conditions Active	na
Conditions Discontinued	Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma
Development Tech	CAT Phage Display